Background: The response to risperidone in patients with schizophrenia is influenced by many factors including the genetic ones. The innovations in biotechnology have provided essential tools for conduction of pharmacogenetic research and subsequently a number of pharmaco-dynamic and pharmaco-kinetic studies delineating the response of anti-psychotics in schizophrenia have been conducted till date. So, we may prevision that pharmaco-genetic knowledge can provide us with the tools to personalize treatment in routine psychiatric clinical practice.
Introduction
Schizophrenia, a severe mental illness, often runs a chronic course and affects the sufferer in multiple ways. Antipsychotics, the mainstay of pharmacological treatment of schizophrenia, are usually chosen following trial and error processes. However, pharmaco-genetics provides us the tools to tailor the drugs for our clients. With improved understanding of the underpinnings of schizophrenia, the field for pharmaco-genetic research has also widened. Although, clozapine had been the choice of drug in most of the existing pharmaco-genetic research, it is not a first line agent in routine clinical practice. In low and middle-income countries, either the first generation or cheaper second-generation antipsychotics are the first choice and clozapine is mostly reserved for resistant cases. Additionally, the genetic differences across populations necessitate exploration of response to antipsychotics in various ethnicities which can be broadly carried out in two ways. Firstly, by utilization of already available information and knowledge regarding the candidate genes (i.e. pharmaco-genetic studies) and secondly, evaluation of new gene markers by using Genome Wide Association Studies (GWAS) through the pharmacogenomics studies 1 .
In view of the increasing interest in pharmaco-genetic research, a brief review of the available pharmaco-genetic research for the effect of various candidate genes on risperidone treatment, as monotherapy, in patients with schizophrenia has been done in this article.
How Does Risperidone Work in Schizophrenia? 2 Smart Art: How does Risperidone Work? (Table 1) The dopamine system has been known to be involved in the etiology of schizophrenia and antipsychotics bind to various dopamine receptors and result in symptomatic improvement. Although, the DRD2 receptor gene is the most sought-after targets, but other dopamine receptor genes have also been shown to influence the response to risperidone.
Role of Dopamine Receptor Genes and Response to Risperidone

Dopamine D2 receptor (DRD2) gene
The commonly studied single nucleotide proteins (SNPs) for DRD2 gene are: Ser311Cys, -141C Del/Ins, Taq1A/B/D, and A-241G. Ser311Cys genotype occurs as a result of the substitution of serine with cysteine at 311 position. The Ser311 variant can modulate receptor and G-protein interaction and risperidone unlike some other antipsychotics has no difference in binding affinity to DRD2 with Ser311. However, Cys311 may have a different response to risperidone due to conformational changes in the receptor protein. Also, the frequency of Cys311 allele is 0.01-0.05 in Europeans and 0.0-0.06 in Asians. Significant association of this SNP with the reduction of psychopathology (decline in PANSS scores) and improved social functioning was shown in a Chinese cohort 3 . But in a recent North Indian study 4 the mutation was absent, however, the frequency was comparable to Caucasians in another study from South India 5 . Furthermore, in an American study 10 , it was shown to be associated with reduction in PANSS negative and total scores in Caucasian patients, but not in African Americans.
The -141C Ins/Del represents a deletion of cytosine at -141 position of 5' promoter region and leads to the lower density of D2 receptors 6 . The deletions have been associated with poor response to most of antipsychotic agents 7 . In case of risperidone although the haplotype of -141C Ins/Del did not affect the response [8] [9] [10] , but when evaluated with Taq1A, the diplotype Ins A2/Del A1 was shown to predict better response 11 
.
Taq1A/B/D polymorphism-The Taq1 A gene/ANKK 1 (Ankyrin repeat and kinase domain containing 1 gene) involves C>T substitution. Taq (A1) allele has been associated with reduced density and thus dopaminergic activity in human brain. On the other hand, Taq1B gene's B1 (C) allele has also been shown to be associated with the reduction of D2 receptor density, especially in the striatum. The A1/A1 genotype of Taq 1A has been shown to predict better outcome with risperidone treatment in only Japanese cohorts 9, 11 and some decline in positive scores on PANSS in African Americans 10 while no association seen in Chinese 8 , Caucasians 10 and Indian schizophrenia patients 4 . Similarly, no association of the Taq1B gene polymorphisms with efficacy of risperidone treatment has been reported in various ethnicities 4, 8 . Taq 1D polymorphism has been studied in both addictive disorders as well as schizophrenia, but without any significant association in a previous Chinese study 8 . However, the D2/D2 genotype predicted non-response to risperidone in the Indian study 4 . Another SNP (-241A> G substitution), with an unknown function, is also commonly studied SNP and it's A-allele has been shown to be associated with better response to risperidone in two out of three studies [8] [9] [10] .
Other dopamine receptor genes
The dysfunction of DRD1(highly expressed in striatum and cerebral cortex) is associated with cognitive defects and negative symptoms of schizophrenia 12 . But genetic studies failed to show association of DRD1 genes and improvement in cognitive/negative symptoms in response to risperidone 9, 13 . The D3-dopaminergic receptors, expressed in limbic system and basal ganglia, affect the cognitive and motor functions. One of the DRD3 gene SNP (Ser9Gly) involves a missense mutation due to substitution of serine to glycine at position 9 and results into an altered dopamine binding affinity. Risperidone has moderate affinity for D3 receptors and the presence of Serine allele was shown to be associated with better response 14 in one study but not in others 9, 15 . Two other studies that evaluated DRD3, DRD4 and DRD5 gene polymorphisms, respectively, did not find significant association with most of the SNPs analyzed (except a decline in PANSS positive score in African American cohort and the rs324028 SNP) 9, 10 .
Box 1
To summarize, at least one study each for various SNPs of DRD2, and one for DRD3 gene (Ser9Gly) polymorphism showed an association with response to risperidone, but none for the rest of dopaminergic receptor genes. However, it will be early to refute the evidence whatsoever available, till further large sample studies in other ethnicities are conducted.
Role of Serotonin Receptor/ Transporter Genes and Response to Risperidone (Table No. 1)
Risperidone has moderate to very high affinity for the serotonergic receptors, which also defines its atypicality. So, the exploration of potential genetic variations in serotonergic receptors/transporter genes and their association with antipsychotic response may provide important insights.
Serotonin receptor 2 (5-HTR2A and 2C) genes
The 5-HT2A receptors are widely distributed in human brain cortex and are the major target of the SGAs which show high binding affinity and associated with improvement in cognitive and negative symptoms. Amongst the various polymorphisms, the T102C is the most commonly studied. This mutation in itself is non-functional, but shown to be in complete linkage disequilibrium to another 5HTR2A SNP namely A-1438G. Studies have found differential impact of this SNP in Caucasian and Asian ethnicities as is their allele frequencies 16 . Patients with C/C or C/T genotypes had been shown to better respond to risperidone in some Asian studies 15, 17 while no association in many other studies was found 3, 4, [9] [10] [11] . However, rs6314 (His452Tyr) was associated with significant decline in the positive and total scores on PANSS in Caucasian population in an American study 10 .
Another recently studied SNP 516T>C in a large North Indian cohort reported that the CT genotype predicted non-response to risperidone 4 . Some of other SNPs (like A-1438G) which have been shown to be associated with improvement in negative symptoms in response to other atypical antipsychotics had no effect in case of risperidone 1 . 5-HTR2C receptors have been shown to be expressed widely in the striatum, prefrontal cortex, limbic system and thus implicated to affect memory, executive functions, eating behavior and motor functions. So, with respect to + Super fix to the PANSS or BPRS or CGI denotes that additional measurement of the plasma concentration of levels of risperidone and its active metabolite 9-hydroxyrisperidone was also done.
risperidone, this gene shall be involved in its response to cognitive symptoms, negative symptoms as well as side effects like weight gain (side effects not reviewed here). The commonly studied SNPs viz. -759C/T, -697G/C and Ser23Cys did not show any association with response 9, 10, 18 . But, 3 other SNPs (rs518147, rs1023574 and rs9698290) were shown to predict the efficacy of risperidone especially in the females 18 
.
Other serotonin receptor genes 5-HTR1A receptors modify the dopaminergic activity and have some role in negative symptoms of schizophrenia. Specifically, one of the functional polymorphism i.e. -1019 C/G (rs6295) has been studied earlier [19] [20] . Its G/G genotype is associated with increased 5HTR1A density in presynaptic neurons in the raphe. But a Chinese study 21 reported that CC genotype of -1019C/G predicted greater improvement in negative symptoms of schizophrenia patients treated with risperidone though the results were not replicated in a Japanese study 9 .
Some of the previous studies have found association of the 5HTR-3A genes (specifically, the R344H and P391R variants), with schizophrenia and bipolar disorder 22 . The 5HT3 receptors have been hypothesized to modulate release of dopamine as well as other neurotransmitters like GABA, substance P, acetylcholine, which in turn may affect the antipsychotic response in patients with schizophrenia. One another SNP (g.14396A>G) was found to be associated with significant decline in the negative symptoms as well as general psychopathology 23 .
The 5-HT6 receptors facilitate serotonin mediated release of dopamine and thus it is hypothesized that drugs acting on this receptor would be beneficial for positive symptoms of schizophrenia. A significant association of the T/T genotype of C267T and reduction of positive symptoms and general psychopathology has been shown in one study 24 but not in two others 9, 10 .
Another serotonergic receptor (5-HT7) to which risperidone binds with high affinity have been shown to be reduced in the prefrontal cortices of patients with schizophrenia 25 . Available research failed to show any association of 5-HT7 polymorphism and response to risperidone in patients with schizophrenia 9, 24, 26 .
The 5-HTT gene codes for the serotonin transporter SLC6A4 (solute carrier family 6 member 4) which mediates serotonin transport into the presynaptic neuron and thus plays role in the termination of extracellular effects of serotonin 27 . One of the repeat length polymorphism (5-HTTLPR) that is an insertion/ deletion of 44-bp segment in the upstream of transcription start site of promoter region has been evaluated in psychiatry especially for the association of antidepressant response. In accordance, the long allele has been shown to be associated with response to risperidone in patients with schizophrenia 28 .
Box 2
In summary, the various serotonin gene polymorphisms, but more so for the 5-HT2 receptor genes, showed some association with response to risperidone in predominantly Han Chinese populations. The latter may be attributed to a great number of pharmaco-genetic research been done in this population only. (Table No. 
Gene Polymorphism of Metabolizing Enzymes and Risperidone Response
Cytochrome P 450 enzyme genes
They have major role in the metabolism of risperidone, and most of the research is in context of its pharmacokinetics (which is not reviewed in this article). However, in a recent study, the CYP2D6 * 4 wild type genotype was associated with better response when the drop outs were not included in the analysis 4 . Another recent research showed association of CYP2D6 SNPs with improvement in the neurocognitive symptoms of schizophrenia 31 . In addition, the CYP2E1 genes (due to their role in catalytic reactions and production of reactive oxygen species) have been linked with onset as well as etiology of schizophrenia 32 . No relationship with efficacy of treatment and gene polymorphisms for CYP2E1 * 1C and * 1D VNTR SNPs was shown in a study done on Han Chinese population 33 . Another Chinese study that analyzed CYP3A4 * 1G variants (common mutations in Chinese population 34 ) was unsuccessful in eliciting an association with risperidone response 35 .
COMT genes
Catechol O-methyl transferase inactivates the postsynaptic dopamine, and thus regulates its availability in the brain. Though it is not directly related to the mechanism of the antipsychotic medications, but some studies showed the association of response to medication and COMT polymorphism 36, 37 . The commonly studied Val158Met SNP has not been shown to affect the response to risperidone 11 , but two other SNPs were found to be related 10, 38 .
Box 3
Gene polymorphisms of the ABCB1/MDR1 but not for the COMT or CYP450 enzymes have been shown to influence the response to risperidone treatment in patients with schizophrenia
Other Gene Polymorphisms and Response to Risperidone (Table No. 1) A part of pharmaco-genetic research has also brought to the fore some of intriguing target genes like the signaling pathways of receptors (Guanine nucleotide binding proteins 21 , Regulator of G-protein signaling/ RGS and RGS-like proteins 39 , glycogen synthase kinase 3 (GSK3)/ AKT) 9 , glutamatergic neurotransmission (metabotropic glutamate receptor/GRM3 10 ), histamine receptors 40 and brain derived neurotrophic factor (BDNF) 41 . Some of these have yielded positive association with response to risperidone in patients with schizophrenia and may be a target for newer GWAS based research as shown by some recent research 42, 43 .
Conclusion
The aim of pharmaco-genetics studies is two pronged. One, they may help in individualizing pharmacotherapy in psychiatry akin to the utilization of antibiotic sensitivity test for infectious disorders. Second, the psychotropic related adverse effects may be minimized. This in turn will have a lot of ramification in form of saving of time to achieve adequate response, provide sustainable relief with minimal discomfort, reducing dysfunction and improving the quality of life, cutting the costs of treatment etc.
In the last decade, reasonable pharmaco-genetic evidence for the role of various genetic polymorphisms in prediction of clinical response to risperidone treatment in schizophrenia has been made available. However, it shall be acknowledged that despite such an advancement of pharmaco-genetic research, it is far from utilization in day to day clinical practice. This limitation is partly due to lack of generalization, ethnical genetic differences, evidence mainly from some select populations, varying study designs, our knowledge about etio-pathogenesis of schizophrenia as well as its phenotypes, interaction of various gene-environment factors etc. However, the advent of newer molecular techniques, refinement of methodology, availability of rapid and cheaper techniques of genetic analysis, and widening the field of research shall help us devise personalized medicine in future.
